医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dicerna to Present at 2014 AsiaTIDES Conference

2014年02月24日 PM11:25
このエントリーをはてなブックマークに追加


 

WATERTOWN, Mass.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced that Bob D Brown, PhD, the Company’s Chief Scientific Officer and SVP, is scheduled to participate in the 2014 AsiaTIDES Conference being held in Tokyo, Japan February 25-27, 2014. Dr. Brown will chair the main conference plenary session of keynote presentations addressing drug delivery systems for peptides and oligonucleotides; give a presentation titled, “Physical and Chemical Characterization of LNP Formulations of Oligonucleotides vs. Biological Activities;” and participate as a panel member discussing delivery approaches and challenges on Thursday, February 27, 2014.

About Dicerna Pharmaceuticals, Inc.

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas and intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.

CONTACT

Investors:
Dicerna Pharmaceuticals, Inc.
James B. Weissman,
617-621-8097
Chief Business Officer
or
Media:
MacDougall
Biomedical Communications
Chris Erdman, 781-235-3060
Senior
Vice President
chris@macbiocom.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Code Corporation Expands Into Australian Healthcare Market, Signs HPA as New Channel Partner
  • Asahi Kasei and Nara Medical University Confirm 226 nm UVC LED Efficacy Against SARS-CoV-2 and Verify Reduced Effect on Animal Skin Cells
  • HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline With Two Lead Immuno-Oncology Programs and Validate Its DIS™ Approach in the Clinic
  • Telix Pharmaceuticals and Applied Radiology Launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
  • アジェンディアのマンマプリント検査、NSABP B-42試験で長期内分泌療法の利点を予測する能力を初めて示す